Business
Biodesix Recognized as a Thermo Fisher Scientific Center of Excellence (COE) for NGS Diagnostics
Biodesix recently validated Thermo Fisher’s tissue-based Oncomine Dx Express Test for solid tumors on the Genexus Dx Integrated SequencerLOUISVILLE, Colo., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leader in personalized diagnostics, announced that the company is designated as a Thermo Fisher Scientific Center of Excellence (COE) as part of Thermo Fisher’s collaborative initiative to advance NGS-based diagnostics. The services provided to Thermo Fisher are an example of
About this update from Thermo Fisher Scientific Inc
[{"type":"image","alt":"Biodesix, Inc.","displaySize":"","headline":null,"caption":"Biodesix, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":110,"url":"https://media.zenfs.com/en/globenewswire.com/cd1b6f0f04b27dd51e3e0af52fefc5f0"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/ZXm0WIRUy_.i8bpwMH7VDQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE1NDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/cd1b6f0f04b27dd51e3e0af52fefc5f0","width":300,"height":110}},"lazy":false},{"type":"text","content":"Biodesix recently validated Thermo Fisher’s tissue-based Oncomine Dx Express Test for solid tumors on the Genexus Dx Integrated Sequencer","length":142,"tagName":"p"},{"type":"text","content":"LOUISVILLE, Colo., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leader in personalized diagnostics, announced that the company is designated as a Thermo Fisher Scientific Center of Excellence (COE) as part of Thermo Fisher’s collaborative initiative to advance NGS-based diagnostics. The services provided to Thermo Fisher are an example of Biodesix Development Services offerings, including customizable options that enable the world’s leading life sciences companies, biopharmaceutical, and medical research institutions with scientific, technological, and operational capabilities.","length":606,"tagName":"p"},{"type":"text","content":"As Thermo Fisher announced in July 2025, Biodesix was an instrumental partner in the validation of the Oncomine Dx Express Test leading to the FDA approval of the Genexus Dx Integrated Sequencer. Biodesix Development Services conducted validation studies utilizing its design-controlled laboratory processes, quality management systems, and contributed data generation in support of regulatory submission.","length":405,"tagName":"p"},{"type":"text","content":"“Working with Thermo Fisher, we continue to forge a path to conquer cancer, and we are delighted to expand our molecular diagnostic and NGS testing capabilities in tissue-based profiling,” said Scott Hutton, CEO at Biodesix. "Being a member of Thermo Fisher’s COE network puts us in excellent company with other global groups committed to transforming cancer diagnosis and care. We are excited about the potential to offer the Oncomine Dx Express Test in the future.”","length":472,"tagName":"p"},{"type":"text","content":"U...